Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07101120
PHASE2

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.

Official title: A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KH607 in the Treatment of Adult Participants With Moderate or Severe Major Depressive Disorder

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-08

Completion Date

2026-04

Last Updated

2025-08-03

Healthy Volunteers

No

Interventions

DRUG

KH607 tablets

oral 30mg , once daily for 14 days

DRUG

placebo

oral, once daily for 21 days

DRUG

KH607 tablets

oral 20mg, once daily for 21 days

DRUG

KH607 tablets

oral 30mg, once daily for 21 days